Predisposing factors for BCR after sEBRT may either originate at the primary tumour site, indicating insufficient local treatment, or from disease outside the prostate bed (i.e., occult metastases), suggesting metastatic disease for which local sEBRT is not appropriate. The gene discussed is BCR; the disease is neoplasm.